STOCK TITAN

Rallybio Corporation to Present at the 4th Annual Evercore ISI HealthCONx Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Rallybio (NASDAQ: RLYB), a clinical-stage biotechnology company, announced its participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 8:00 a.m. ET. The company will engage in a virtual fireside chat and conduct one-on-one meetings on the same day. A webcast of the presentation will be available on Rallybio’s website, with an archived replay accessible for 30 days post-event. Founded in January 2018, Rallybio aims to develop therapies for severe and rare diseases across various medical fields.

Positive
  • None.
Negative
  • None.

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 8:00 a.m. ET. Rallybio will also host one-on-one meetings on the same day.

A webcast of the presentation will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.

About Rallybio

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

Investor Contacts

Steven Tuch

investors@rallybio.com

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Media Contact

Tara DiMilia

908-369-7168

Tara.dimilia@tmstrat.com

Source: Rallybio Corporation

FAQ

When is Rallybio's presentation at the Evercore ISI HealthCONx Conference?

Rallybio's presentation is scheduled for December 1, 2021, at 8:00 a.m. ET.

Where can I watch the Rallybio conference presentation?

The presentation can be watched via the Events and Presentations section on Rallybio’s website.

What is the focus of Rallybio's therapies?

Rallybio focuses on developing therapies for severe and rare diseases, particularly in hematology, immuno-inflammation, maternal fetal health, and metabolic disorders.

How long will the Rallybio conference webcast be available?

The archived replay of the webcast will be available for 30 days following the presentation.

What is the significance of the Evercore ISI HealthCONx Conference for Rallybio?

The conference offers Rallybio an opportunity to engage with investors and discuss its ongoing developments in rare disease therapies.

Rallybio Corporation

NASDAQ:RLYB

RLYB Rankings

RLYB Latest News

RLYB Stock Data

40.27M
41.49M
4.06%
76.95%
1.29%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW HAVEN